Before 2017, drug companies will suffer patent losses of $140 billion.
Reuters, May 1, 2007
Now is the time for pharmaceutical companies – both brand name and generic – to rethink patent strategies not only in terms of this impending economic reality, but also in terms of the dramatic changes to the patent landscape on every front – in Congress, at the PTO, and in the courts.
American Conference Institute’s 9th Annual Maximizing Pharmaceutical Patent Life Cycles will be held October 15-16, 2008, in New York, NY.
Patent counsel and advisors to leading pharmaceutical companies, as well as representatives from key government agencies will provide insights on the latest Hatch-Waxman challenges and bring you the latest legal strategies and tactics for successful maneuvering in the revised patent endgame. With all that’s at stake, you cannot afford to miss this conference.
Related posts:
- Maximizing Pharmaceutical Patent Lifecycles The American Conference Institute’s Maximizing Pharmaceutical Patent Lifecycles, the 10th...
- FDA and Xavier University Host Global Outsourcing Conference The FDA and Xavier University have co-developed the first annual...
- Mid-Atlantic Bio Looking For Emerging Companies Calling Emerging Company Presenters Application Deadline is September 23 Company...
- Special Life Science Event : Commercializing and Funding Biotechnology Opportunities Forum on Commercializing and Funding Biotechnology Opportunities Faculty, researchers, entrepreneurs...
- Australian Pharmaceutical Patent Term Extension for Patches and Implants Bill Bennett, of Pizzeys in Australia, sent a note detailing...
Related posts brought to you by Yet Another Related Posts Plugin.
